Difference between revisions of "Strontium-89 (Metastron)"
Jump to navigation
Jump to search
m |
m |
||
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *1993-06-18: Initial approval for the relief of bone pain in patients with painful skeletal metastases. |
==Also known as== | ==Also known as== | ||
| Line 16: | Line 16: | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
[[Category:FDA approved in 1993]] | [[Category:FDA approved in 1993]] | ||
| + | [[Category:Stub]] | ||
Revision as of 18:28, 7 April 2023
General information
Radioactive strontium
Diseases for which it was used
History of changes in FDA indication
- 1993-06-18: Initial approval for the relief of bone pain in patients with painful skeletal metastases.
Also known as
- Brand name: Metastron